Reset filter
Keywords
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

2200 Search results.
Relevance Rating New first Old first

Eligibility DRKS00009656 NCT00069745 Prostate Cancer - Eligibility

- 9/20/21 - 1 form, 3 itemgroups, 34 items, 2 languages
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Inclusion Criteria: - Stage D2 metastatic prostate cancer - Progression after one prior chemotherapy - ECOG Performance status equal / less than 2 - Life expectancy > 3 months - Surgical or medical castration - Adequate bone marrow, hepatic and renal functions - Informed consent Exclusion Criteria: - More than one prior chemotherapy - Prior platinum containing compounds - Prior malignancy - Prior significant RT/radionuclide therapy - Major GI surgery or GI disease affecting absorption - Disease with contraindication to steroids - Brain metastases

A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052 - Eligibility Bladder Cancer NCT00661609

- 9/27/21 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609

Eligibility DRKS00003645 NCT00349076 Rectal Neoplasms - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00349076

NCI COOPERATIVE GROUP Patient Information FORM (CALGB-90104)

- 9/20/21 - 1 form, 6 itemgroups, 41 items, 1 language
Itemgroups: MSKCC 00-138; CALGB-90104; ECOG, Protocol Administration, Patient Demographics / Pre-Treatment Characteristics, Certification of Eligibility, Protocol Design, Initial Patient Consent for Specimen Use
NCI COOPERATIVE GROUP Patient Information FORM (CALGB-90104) Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A9BED937-4416-2507-E034-0003BA12F5E7

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 9/17/21 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion criteria, Exclusion criteria
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Eligibility NCT00655252 Metastatic Renal Cell Cancer - Eligibility

- 12/9/13 - 1 form, 2 itemgroups, 10 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00655252

Eligibility DRKS00003984 NCT00887198 Prostate Cancer - Eligibility

- 4/17/14 - 1 form, 2 itemgroups, 10 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00887198

Eligibility DRKS00003880 NCT00273338 Prostate Cancer - Eligibility

- 4/13/14 - 1 form, 3 itemgroups, 35 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria, Medical Concepts
ODM derived from http://clinicaltrials.gov/show/NCT00273338

Eligibility DRKS00009647 NCT00036543 Prostate Cancer - Eligibility

- 12/9/13 - 1 form, 3 itemgroups, 11 items, 2 languages
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer Inclusion Criteria: - Diagnosis of prostate cancer. - Rising PSA while on hormonal therapy or following surgical castration. - Documented evidence of metastatic disease. Exclusion Criteria: - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months

Eligibility NCT00844064 Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 33 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00844064

Bladder Cancer NCT00014534 Treatment - CALGB: 90104 Eligibility Checklist - 2169226v3.0 - CALGB: 90104 Eligibility Checklist

- 1/9/15 - 1 form, 1 itemgroup, 36 items, 1 language
Itemgroup: CCRR MODULE
CALGB: 90104 Eligibility Checklist Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE19FD2A-E369-6ABF-E034-0003BA12F5E7

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 12/11/13 - 1 form, 2 itemgroups, 7 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00246974

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial